Document:

Unassociated Document

Exhibit 10.17

 

RESTRICTED STOCK UNIT AWARD AGREEMENT

UNDER THE ANTHERA PHARMACEUTICALS, INC.

2013 STOCK OPTION AND INCENTIVE PLAN

 

	
Name of Grantee:

	  
	
No. of Restricted Stock Units Granted:

	  
	
Grant Date:

	  
	
Grant Date Fair Value:

	  

 

 

Pursuant to the Anthera Pharmaceuticals, Inc. 2013 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Anthera Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.001 per share (the “Stock”) of the Company,

 

1.           Restrictions on Transfer of Award.  The Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Section 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.

 

2.           Vesting of Restricted Stock Units.  The Restricted Stock Units shall vest in accordance with the schedule set forth below, provided in each case that the Grantee is then, and since the Grant Date has continuously been, employed by the Company or its Subsidiaries.

 

	
Incremental (Aggregate)

Number of

Restricted Stock Units Vested

	
 

 

Vesting Date

	
 
                               (       %)

	
                             

	
 
                               (       %)

	
 
                             

	
 
                               (       %)

	
 
                             

The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3.

 

3.           Termination of Employment.  If the Grantee’s employment with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Section 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.

 

4.           Receipt of Shares of Stock.  As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Section 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.

 

  

  

  

 

5.           Incorporation of Plan.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

 

6.           Tax Withholding.   The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.  The Company shall have the authority to cause the required minimum tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due.

 

7.           No Obligation to Continue Employment.  Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time.

 

8.           Notices.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

	  	ANTHERA PHARMACEUTICALS, INC.
	 	 	 
	 	 	 
	 	 	 
	 	

By:   

	  
	  	 	
Name:

	  	 	
Title:

  

2

  

 

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.

 

 

	  	
  

 

	  	
Grantee’s Signature

	 	 
	 	 
	  	
Grantee’s name and Address

	  	
  

 

	  	
  

 

 

 

 

 

 3ex10_31.htm

Exhibit 10.31

 

ANTHERA PHARMACEUTICALS, INC.

Deferred Compensation Election Form

 

 

	
I.

	
Elective Deferral Percentages

 

As specified below, I elect pursuant to the Deferred Compensation Agreement entered into by Anthera Pharmaceuticals, Inc. (the “Company”) and me as of the 7th day of December, 2013  (the “Deferred Compensation Agreement”) to defer receipt of that percentage of my Eligible Compensation which would otherwise be paid to me for services during 2014 (with respect to compensation earned with respect to services to be performed by me subsequent to the date of this election) and subsequent calendar years:

 

	
Deferral Percentage:

	
Base Annual Salary:

	
35%

	  	
Annual Bonus:

	
40%

 

I understand that this election is irrevocable for 2014 and that unless and until this election is changed prospectively for future calendar years on a new election form before those years begin, this election shall continue as shown above for all subsequent calendar years.  Capitalized terms used in this election will have the meaning given such terms in the Deferred Compensation Agreement.

 

	
II.

	
Form and Timing of Payment of Account

 

I understand that my Account will be paid to me upon the first to occur of the dates specified in Section 3 of the Deferred Compensation Agreement and that I may specify a date for subsection (i) of such Section 3.  The date I specify for subsection (i) of Section 3 of the Deferred Compensation Agreement is January 1, 2017.  I understand that if I do not specify a date, that the Account will be paid to me upon the first to occur of the dates/events specified in subsections (ii) through (v) of Section 3 of the Deferred Compensation Agreement.  At the End of the Deferral Period, my Account will be paid as specified in Section 4 of the Deferred Compensation Agreement, subject to the requirements of Section 8 of the Deferred Compensation Agreement.

 

I understand that any amounts deferred by this election and any other amounts deferred by me pursuant to the Deferred Compensation Agreement shall be credited to a bookkeeping account established for me by the Company and that any segregation of Company assets intended to satisfy the obligations of the Company under the Deferred Compensation Agreement shall not confer a beneficial ownership interest on me and any such assets shall remain subject to the claims of the general creditors of the Company in the event of the bankruptcy or insolvency of the Company.

 

Executed on the date specified below.

 

  

  

  

 

	           	 	 	December 7th, 2013
	Executive: Paul F. Truex 	 	    Date     	 
	Title: President & CEO	 	 	 

 

 

Receipt of Form by Company

 

	Received by:	 	 
	 	 	 

	
Title:  SVP Finance & Administration & Principal Accounting Officer

	 	 

 

	
Date signed:  December 7th 2013ex10_27.htm

Exhibit 10.27

 

 

 

 

November 14, 2013

 

Mr. Ed Dy

Anthera Pharmaceuticals, Inc. 

25801 Industrial Blvd.

Suite 200

Hayward CA 94545

 

RE:         25801 Industrial Blvd., Suite 200

First Amendment to Lease

 

Dear Ed:

 

Enclosed is the fully executed First Amendment to Lease extending your lease to September 30, 2017.

 

Also, in follow up to my email of November 6th, during a recent audit we discovered we never received the security deposit of $13,893.66 as outlined in section 3.3 of your Lease.

 

Please submit payment as soon as possible to:

 

MEPT Mount Eden LLC

PM Box #05899-05 

P.O. Box 39000

San Francisco, CA 94139-5899

 

We look forward to continuing to work with you and the Anthera team and wish you continued success.

 

Should you have any questions, please contact me. 

 

Thank you,

 

Sincerely,

SIMEON Commercial Properties, LLC

Barbara M. Wells

VP Property Management

 

Enclosure

 

 

655 MONTGOMERY STREET, SUITE 1190 SAN FRANCISCO, CA 94111-2658

PH: 415.986.2002 - FAX: 415.986.2130 - www.simeonproperties.com

  

  

  

 

FIRST AMENDMENT TO LEASE

 

THIS FIRST AMENDMENT TO LEASE (“Agreement”) dated as of    11-13-13       , 2013, is made and entered into by and between MEPT Mount Eden LLC, a Delaware limited liability company (“Landlord”) and Anthera Pharmaceuticals, Inc., a Delaware corporation (“Tenant”).

 

BACKGROUND

 

A.          Landlord and Tenant entered into that certain Lease dated May 4, 2011 (the “Lease”), covering certain premises located in the Mt. Eden Business Park consisting of approximately 14,034 rentable square feet of space (the “Premises”) in the building at 25801 Industrial Blvd., Hayward, CA, commonly known as Building A.

 

B.          The current expiration date of the Lease is September 30, 2014.

 

C.          Landlord and Tenant desire to extend the Term of the Lease for an additional thirty-six (36) months on the terms and conditions set forth in this Agreement.

 

D.          Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Lease.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the covenants and agreements contained herein, the parties hereby mutually agree as follows:

 

1.           LEASE TERM. The Term of the Lease is hereby extended by thirty-six (36) months from October 1, 2014 to terminate on September 30, 2017.

 

2.           BASE RENT AND OPERATING EXPENSES. Effective as of September 15, 2014 (the “Effective Date”), the definition of “Base Rent” in the Lease is hereby amended to reflect that the Base Rent for the Premises shall be as set forth below, payable in equal monthly installments, in advance, on the first business day of each and every month of the Term.

 

PREMISES (14,034 RSF)

 

	
Applicable Portion of Lease Term

	
Monthly Base

Rent, NNN

	
Annual Base Rent,

NNN

	
Beginning first day of:

 

	
Ending last day of:

	  	  
	
October 1, 2014

 

	
September 30, 2015

	
$13,332.30

	
$159,987.60

	
October 1, 2015

 

	
September 30, 2016

	
$13,732.27

	
$164,787.24

	
October 1, 2016

	
September 30, 2017

 

	
$14,144.24

	
$169,730.88

 

  

1

  

 

3.           AUTHORITY. Tenant represents and warrants that all necessary corporate actions have been duly taken to permit Tenant to enter into this Agreement and that the person signing this Agreement on behalf of Tenant has been duly authorized and instructed to execute this Agreement. Landlord represents and warrants that all necessary company actions have been duly taken to permit Landlord to enter into this Agreement and that the person signing this Agreement on behalf of Landlord has been duly authorized and instructed to sign this Agreement.

 

4.           BROKERS. Each of Landlord and Tenant warrants and represents that it has dealt with no real estate broker in connection with this Agreement, and that no broker is entitled to any commission on account of this Agreement. The party who breaches this warranty shall defend, hold harmless and indemnify the other from any loss, cost, damage or expense, including reasonable attorneys’ fees, arising from the breach.

 

5.           FULL FORCE AND EFFECT. Except as expressly modified above, all terms and conditions of the Lease remain in full force and effect and are hereby ratified and confirmed. Landlord and Tenant hereby acknowledge and agree that, except as provided in this Agreement, the Original Lease has not been modified, amended, canceled, terminated, released, superseded or otherwise rendered of no force or effect.

 

6.           LANDLORD’S AND TENANT’S ADDRESSES. Landlord’s and Tenant’s addresses for purposes of notices under the Lease are hereby revised to be the addresses set forth opposite Landlord’s and Tenant’s signatures below.

 

7.           COUNTERPARTS. This Agreement may be executed in counterparts. It is the intention of the parties that any executed counterpart shall constitute the agreement of the parties and that all of the counterparts shall together constitute one and the same agreement of the parties.

 

8.           FACSIMILE EXECUTION. Any facsimile transmittal of original signature versions of this Agreement shall be considered to have the same legal effect as execution and delivery of the original document and shall be treated in all manner and respects as the original document. The parties also agree to promptly exchange counterparts with original signatures.

  

2

  

 

IN WITNESS WHREOF, this Agreement is executed and delivered as of the date and year first above written.

 

	
Designated Address for Landlord:

	
LANDLORD:

	 	 
	 	 
	
MEPT Mount Eden LLC

c/o Bentall Kennedy (U.S.) Limited 

Partnership

	
MEPT Mount Eden LLC, a Delaware limited 

liability company

	Attn: Dir. of Asset Management - MEPT 

1215 Fourth Avenue, Suite 2400

	By:	MEPT Edgemoor REIT LLC, a Delaware limited

liability company, its Manger

	Seattle, WA 98161 	 	 
	
Facsimile:  206-682-4769

	 	By:	
Bentall Kennedy (U.S.) Limited 

Partnership, its Authorized Signatory

	and to:	 	 	 	 
	
 

MEPT Mount Eden LLC

	 	 	By:	
Bentall Kennedy (U.S.) G.P.

LLC, its General Partner

	c/o NewTower Trust company 

Attn: President/MEPT or Patrick O. 

Mayberry

3 Bethesda Metro Center, Suite 1600

Bethesda, MD 20814

Facsimile:  240-235-9961

	 	 	
	 	 	 	 	 
	
Designated Address for Tenant:

 

Anthera Pharmaceuticals, Inc.

	TENANT:                                              11/13/13

 

Anthera Pharmaceuticals, Inc., a Delaware 

	
Attn:                                            

	
corporation

	
25801 Industrial Blvd., Suite 200

Hayward, CA 94545

Phone:                                        

Facsimile:                                   

	

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]